FDA Approves AstraZeneca to Market Crestor to People without Cholesterol Problems
February 9, 2010 /EIN PRESSWIRE/ AstraZeneca has won FDA approval to market its cholesterol drug Crestor to people who have healthy cholesterol levels. Crestor can now be marketed to certain groups as a drug that can help reduce the risk of heart attack and stroke.
According to the AP, a 2008 study showed that Crestor reduced heart attacks, strokes and other problems by 44% in patients with normal cholesterol and slight heart disease risks. All patients had an elevated level of C-reactive protein, which is an indicator of inflammation that can lead to heart attack or stroke.
The FDA has now approved Crestor for men over 50 and women over 60 and who have elevated C-reactive protein levels and at least one risk factor for heart trouble, such as high blood pressure or a smoking habit.
Crestor is already AstraZeneca's third-best-selling drug, with revenue rising 29% to $4.5 billion last year, and now the FDA has cleared the way for up to 6 million more people in the US to buy the drug.
Read more about this story at Pharmaceutical Industry Today:
Latest Crestor news - http://pharmaceuticals.einnews.com/news/crestor
Latest AstraZeneca news - http://pharmaceuticals.einnews.com/news/astra-zeneca
Located at http://pharmaceuticals.einnews.com, Pharmaceutical Industry Today is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest pharmaceutical news from around the world, saving them valuable time they'd spend searching for information. New users to Pharmaceutical Industry Today can enjoy a no-obligation, one-week free trial.
About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.
According to the AP, a 2008 study showed that Crestor reduced heart attacks, strokes and other problems by 44% in patients with normal cholesterol and slight heart disease risks. All patients had an elevated level of C-reactive protein, which is an indicator of inflammation that can lead to heart attack or stroke.
The FDA has now approved Crestor for men over 50 and women over 60 and who have elevated C-reactive protein levels and at least one risk factor for heart trouble, such as high blood pressure or a smoking habit.
Crestor is already AstraZeneca's third-best-selling drug, with revenue rising 29% to $4.5 billion last year, and now the FDA has cleared the way for up to 6 million more people in the US to buy the drug.
Read more about this story at Pharmaceutical Industry Today:
Latest Crestor news - http://pharmaceuticals.einnews.com/news/crestor
Latest AstraZeneca news - http://pharmaceuticals.einnews.com/news/astra-zeneca
Located at http://pharmaceuticals.einnews.com, Pharmaceutical Industry Today is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest pharmaceutical news from around the world, saving them valuable time they'd spend searching for information. New users to Pharmaceutical Industry Today can enjoy a no-obligation, one-week free trial.
About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.
Follow us
What people say
“We have generated many, many press clippings and improved our SEO ranking from the services that EIN Presswire provides us. Easy and simple way to upload and distribute our press releases. I would recommend their services.”
— Chris Morris, Marketing Manager of Mountz Inc.
“I have been using the EIN Press Release service for more than three years in entertainment & health care industries. Their account managers and the placement of my press releases online has been above reproach reaching mainstream journalists to help further client and brand visibility. I highly recommend this service for global notoriety and am thankful I made that first call.“
— Monica Anders PR Strategist 25 Years!
Our Partners
Press releases
- CEO Says the Biggest Super Bowl Party This Year Just Might Be on Facebook [04 Feb 2012] 24-7 pressrelease
- The Importance of Applying for SSDI Benefits After a Serious Diagnosis [04 Feb 2012] 24-7 pressrelease
© 2005-2012